Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lung Neoplasms

Lung Neoplasms

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Neoplasms

31 trials tracked for Lung Neoplasms: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 390 citations.

31Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 15 Phase 1 1 Other / NA 12
  1. Phase 3 Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC Completed · 390 cited
  2. Phase 3 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting Completed
  3. Phase 3 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) Completed
  4. Phase 2 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer Completed
  5. Phase 2 Icotinib for Completed Resected IB NSCLC With EGFR Mutation Completed
  6. Phase 2 LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung Completed
Show 25 more trials
  1. Phase 2 Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) Completed
  2. Phase 2 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen Completed
  3. Phase 2 Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer Completed
  4. Phase 2 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Completed
  5. Phase 2 Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) Completed
  6. Phase 2 Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer Completed
  7. Phase 2 Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Completed
  8. Phase 2 Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer Completed
  9. Phase 2 A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed
  10. Phase 2 Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Completed
  11. Phase 2 OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules Completed
  12. Phase 2 Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease Completed
  13. Phase 1 Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Completed
  14. N/A Improving Communication About Serious Illness Completed
  15. N/A Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer Completed
  16. N/A Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients Completed
  17. N/A Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. Completed
  18. N/A Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer Completed
  19. N/A Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2) Completed
  20. N/A Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment Completed
  21. N/A An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed Completed
  22. N/A Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare® Completed
  23. N/A End-of-Life Care for African Americans Completed
  24. N/A Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening Completed
  25. N/A The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Lung Neoplasms: what the trials found

Clinical evidence for lung neoplasms includes the use of Sintilimab 1 and OTL38 for injection [3, 7]. Tecemotide (L-BLP25) has demonstrated a statistically significant improvement in overall survival time (17.2 vs. 13.0; p=0.045) 11. Safety data for Tecemotide indicates that in a cohort of 22 patients, there were 22 treatment-emergent adverse events (TEAEs), 4 serious TEAEs, and 13 TEAEs of CALGB-ECTC Grade 3 or 4 12.

In a large Phase 3 trial evaluating Pembrolizumab/Vibostolimab, no statistically significant differences were observed in overall survival (OS) across different PD-L1 expression levels: OS was 15.7 vs. 20.3 (p=0.6712) for PD-L1 TPS ≥50%, 15.0 vs. 16.4 (p=0.3320) for PD-L1 TPS ≥1%, and 14.3 vs. 14.3 (p=0.1646) for PD-L1 TPS 1% to 49% 2.

Recent results — preliminary, needs further review

  • The combination of Olaparib and EP0057 (CLRX101) showed a progression-free survival (PFS) rate of 2 at 16 weeks in small cell lung cancer (SCLC) 4.
  • In a study of osimertinib, no significant difference was found in progression-free survival (PFS 1) (14.7 vs. 11.0; p=0.56) or in the specific cohorts for local ablative therapy (PFS 2) (4.0; 3.6; 3.7; p=0.40) 6.
  • Afatinib showed a statistically significant improvement in time to treatment failure (TTF) (13.67 vs. 11.53; p=0.0136), though it did not reach significance for progression-free survival (p=0.0891) or overall survival (p=0.2343) 10.
  • Romiplostim showed no significant difference in the duration of Grade 3 or 4 thrombocytopenia (p=0.972) or the number of patients requiring platelet transfusions (p=1.000) 17.

For the clinician treating this condition

  • Tecemotide (L-BLP25) is associated with a statistically significant improvement in overall survival time in patients with lung neoplasms 11.
  • Pembrolizumab/Vibostolimab did not demonstrate a statistically significant difference in overall survival across various PD-L1 expression thresholds 2.
  • Afatinib demonstrated a statistically significant improvement in time to treatment failure (TTF) in the studied population 10.

AI synthesis of 8 cited trials, updated Sep 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Robotic-assisted bronchoscopy provides comparable diagnostic yield to CT-guided biopsy for peripheral pulmonary lesions
Oncology Meta-analysis
Robotic-assisted bronchoscopy provides comparable diagnostic yield to CT-guided biopsy for peripheral pulmonary lesions Robotic Bronchoscopy Shows Fewer Complications for Lung Lesion Biopsies
This meta-analysis compared robotic-assisted bronchoscopy (RAB) to computed tomography-guided transthoracic needle biopsy (CTTB) for diagnos…
Robotic-assisted bronchoscopy may offer a safer way to biopsy lung lesions by reducing the risk of serious chest complications compared to n…
Sep 9, 2026